Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

INNOVENTA MEDICA ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 2.2% 2.2%   Bankruptcy risk   1.3% 1.2% 4.4% 3.0% 0.9% 1.3% 9.2% 9.0%   Credit score (0-100)   82 82 47 56 90 79 27 27   Credit rating   A A BBB BBB A A BB BB   Credit limit (kDKK)   58.2 60.5 0.0 0.0 292.8 62.1 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   1,272 1,206 728 1,439 1,901 1,391 0.0 0.0   EBITDA   549 282 -283 483 854 319 0.0 0.0   EBIT   549 282 -285 461 832 294 0.0 0.0   Pre-tax profit (PTP)   548.4 296.6 -588.9 -170.1 836.8 333.2 0.0 0.0   Net earnings   427.7 231.3 -466.8 -226.3 652.7 259.0 0.0 0.0   Pre-tax profit without non-rec. items   548 297 -589 -170 837 333 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 109 86.5 64.4 224 0.0 0.0   Shareholders equity total   2,143 2,374 1,908 1,681 2,334 2,593 2,443 2,443   Interest-bearing liabilities   7.3 89.0 199 535 763 619 0.0 0.0   Balance sheet total (assets)   2,845 3,127 2,705 2,798 3,484 3,967 2,443 2,443   Net Debt   -1,498 -664 -166 80.8 -782 -643 -2,443 -2,443     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   1,272 1,206 728 1,439 1,901 1,391 0.0 0.0   Gross profit growth   135.1% -5.2% -39.6% 97.6% 32.1% -26.8% -100.0% 0.0%   Employees   2 2 2 2 2 2 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   2,845 3,127 2,705 2,798 3,484 3,967 2,443 2,443   Balance sheet change%   41.7% 9.9% -13.5% 3.4% 24.5% 13.9% -38.4% 0.0%   Added value   548.7 282.0 -282.8 483.2 854.1 318.9 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 107 -44 -44 134 -224 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 -1.0 1.0 2.0 3.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   43.1% 23.4% -39.1% 32.0% 43.8% 21.1% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   22.6% 10.0% 3.7% 42.2% 28.0% 9.3% 0.0% 0.0%   ROI %   28.1% 12.8% -25.2% -7.0% 32.7% 10.9% 0.0% 0.0%   ROE %   22.2% 10.2% -21.8% -12.6% 32.5% 10.5% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   75.3% 75.9% 70.5% 60.1% 67.0% 65.4% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -273.0% -235.4% 58.7% 16.7% -91.5% -201.7% 0.0% 0.0%   Gearing %   0.3% 3.7% 10.4% 31.8% 32.7% 23.9% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   5.0% 5.1% 7.4% 4.5% 6.5% 1.7% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   3.4 2.0 1.4 1.6 2.1 1.9 0.0 0.0   Current Ratio   3.6 2.3 1.5 1.7 2.2 2.1 0.0 0.0   Cash and cash equivalent   1,505.6 752.8 364.4 454.6 1,544.7 1,262.1 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   1,769.5 893.1 388.4 789.5 1,392.2 1,460.0 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   274 141 -141 242 427 159 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   274 141 -141 242 427 159 0 0   EBIT / employee   274 141 -143 231 416 147 0 0   Net earnings / employee   214 116 -233 -113 326 129 0 0